Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Area of Science:

• Oncology
• Clinical Trials
• Regulatory Science

Background:

• Subgroup analyses assess treatment effects in specific patient populations within oncology trials.
• Their application in regulatory decision-making and product labeling presents significant challenges for the U.S. Food and Drug Administration (FDA).

Purpose of the Study:

• To summarize key issues concerning subgroup analyses in the benefit-risk assessment of cancer drugs.
• To illustrate the FDA Oncology Center of Excellence's approaches to defining appropriate patient populations for drug approval using case examples.

Main Methods:

• Review of existing literature and FDA case examples related to subgroup analyses in oncology drug approvals.
• Analysis of factors influencing regulatory decisions, including statistical efficacy, disease pathophysiology, mechanistic justification, safety, and external data.

Main Results:

• Drugs are typically approved for the total studied population, but exceptions exist for subgroup restrictions or extensions.
• Hypothesis-driven subgroup analyses with adequate sample size are crucial for demonstrating treatment effects.
• Labeling decisions integrate statistical efficacy with mechanistic, safety, and external data.

Conclusions:

• The FDA Oncology Center of Excellence considers the totality of evidence for benefit-risk assessment.
• Final indications and labeling aim to accurately reflect scientific evidence for safe and effective use in specific patient populations.
• Appropriate use of subgroup analyses is vital for precise cancer drug indications.